LPCN

Lipocine Inc.

7.43

USD

LPCN Earnings Reports

Positive Surprise Ratio

LPCN beat 28 of 41 last estimates.

68%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$102.00K

-$0.54

Implied change from Q4 25 (Revenue/ EPS)

-91.10%

+28.57%

Implied change from Q1 25 (Revenue/ EPS)

+9.68%

+54.29%

Lipocine Inc. earnings per share and revenue

On Mar 10, 2026, LPCN reported earnings of -0.42 USD per share (EPS) for Q4 25, beating the estimate of -0.62 USD, resulting in a 32.50% surprise. Revenue reached 1.15 million, compared to an expected 118.32 thousand, with a 868.56% difference. The market reacted with a -10.46% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.54 USD, with revenue projected to reach 102.00 thousand USD, implying an increase of 28.57% EPS, and decrease of -91.10% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Theravance Biopharma, Inc.

Report Date

Mar 19, 2026 For Q4 25

Estimate

$1.24

Actual

$0.21

Surprise

-83.12%

Relmada Therapeutics, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.14

Actual

-$0.28

Surprise

-103.08%

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

NRX Pharmaceuticals, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.01

Surprise

-361.54%

FAQ

What were Lipocine Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Lipocine Inc. reported EPS of -$0.42, beating estimates by 32.5%, and revenue of $1.15M, 868.56% above expectations.

How did the market react to Lipocine Inc.'s Q4 2025 earnings?

The stock price moved down -10.46%, changed from $8.99 before the earnings release to $8.05 the day after.

When is Lipocine Inc. expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for Lipocine Inc.'s next earnings report?

Based on 3 analysts, Lipocine Inc. is expected to report EPS of -$0.54 and revenue of $102.00K for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.